RIVERSIDE, Calif., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Ingen Technologies Inc. (OTC:IGNT), (http://ingen-tech.com) announces today that it has launched a global consumer commercial for its medical division at the same time when 100 Oxyview Units were shipped to the Department of Homeland Security on September 5, 2013; where recently the Department of Homeland Security purchased 100 Oxyview Units for the US Coast Guard and continues to have a serious interest in the patented respiratory products manufactured by Ingen Technologies.
The commercial can be seen on the OTC Video tab at: http://www.otcmarkets.com/stock/IGNT/video-and-presentations
The company has received large purchase orders from the Department of the Interior and the Department of Homeland Security in the past 90 days; an indication that the proprietary patented medical technology is of serious consideration for use with various government and commercial applications.
"The commercial was launched as part of our new marketing program to target the projected $50M annual sales for Ingen. There is serious interest in the acquisition of our medical division, and we are undecided on accepting an offer at this time. Our new Telecom Division has recently landed contracts with TATA Communications and China Unicom, two giants in the global telecom services industry. Our focus is on revenues, and our medical division has suddenly demonstrated great potential with the $8B Respiratory markets," stated Gary Tilden, Chairman.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
Source:Ingen Technologies, Inc.